title: Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine.
abstract: In a study evaluating the efficacy and safety of lansoprazole to prevent the relapse of erosive esophagitis (EE), 206 of 241 patients (85%) healed after open-label treatment with lansoprazole 30 mg once daily for 8 weeks and received double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily for up to 1 year. At 1 year, 67% of lansoprazole-treated and 13% of ranitidine-treated patients remained healed (P<0.001). Lansoprazole-treated patients experienced significantly greater symptom relief (P<0.001), and, if asymptomatic at entry into the maintenance phase, remained asymptomatic for significantly longer than ranitidine-treated patients (P<0.001). Symptom status correlated with healing (P=0.001), supporting the symptom-directed management of EE. Both treatments were well tolerated and no unexpected events occurred. Daily therapy with lansoprazole to prevent the relapse of EE is effective, well tolerated, and superior to ranitidine in the maintenance of healing and symptom relief.
authors: University of Virginia Health System, Charlottesville, VA 22908-0708, USA. dap8v@virginia.edu
authors: David A
authors: DA
authors: Peura
authors: James W
authors: JW
authors: Freston
authors: Marian M
authors: MM
authors: Haber
authors: Thomas O
authors: TO
authors: Kovacs
authors: Barbara
authors: B
authors: Hunt
authors: Stuart
authors: S
authors: Atkinson
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004941:Esophagitis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011788:Quality of Life; D011899:Ranitidine / Q000008:administration & dosage* / Q000009:adverse effects; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014945:Wound Healing / Q000187:drug effects; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D011899:Ranitidine